RxDoctor Payments Data

Geoffrey Gonzales

Psychiatric/Mental Health · San Antonio, TXNPI 1093030512

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $34,656 of the $56,839 with a category attached, or 61.0%. Teva Pharmaceuticals USA, Inc. accounts for 74.6% of it on its own, with 25 other manufacturers making up the rest. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,839in general payments, 2019–2025

Across 1,010 payments — averaging $56.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$42K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
  • Johnson & Johnson$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Neurocrine Biosciences, Inc.$2K
  • AbbVie$2K
  • plus $5K from 20 others

What the payments were for

  • Consulting fees$3301%
  • Speaking & faculty fees$34,65661%
  • Travel & lodging$4,4968%
  • Food & beverage$17,22030%
  • Education$1370%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,839 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$28,787
Medicare patients
72
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine32$253,066
IngrezzaValbenazine Tosylate26$224,599
Invega TrinzaPaliperidone Palmitate17$172,312
VraylarCariprazine Hcl90$145,425
LybalviOlanzapine/Samidorphan Malate47$84,827
Invega SustennaPaliperidone Palmitate31$83,262
RexultiBrexpiprazole49$78,277
CaplytaLumateperone Tosylate44$75,569
SpravatoEsketamine Hcl35$73,679
TrintellixVortioxetine Hydrobromide90$73,307
Abilify MaintenaAripiprazole15$36,773
LatudaLurasidone Hcl13$27,967
AuvelityDextromethorphan Hbr/Bupropion16$27,093
FanaptIloperidone12$23,638
BelsomraSuvorexant26$18,065

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Spravato$1,908$329,25283 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$42,394$253,06632 claims
Neurocrine Biosciences, Inc.Ingrezza$1,573$224,59926 claims
AbbVieVraylar$1,537$145,42590 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$1,718$115,05064 claims
Alkermes, Inc.Lybalvi$1,300$84,82747 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$2,685$75,56944 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$282$73,30790 claims
Sunovion Pharmaceuticals Inc.Latuda$468$27,96713 claims
Axsome Therapeutics, Inc.Auvelity$366$27,09316 claims
Vanda Pharmaceuticals Inc.Fanapt$512$23,63812 claims
MerckBelsomra$99$18,06526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →